PHP
AMLX icon

Parkman Healthcare Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Parkman Healthcare Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.16M Sell
398,782
-222,676
-36% -$3.44M 0.73% 48
2026
Q1 		$8.64M Buy
621,458
+239,698
+63% +$3.37M 0.89% 43
2025
Q4 		$4.61M Sell
381,760
-197,414
-34% -$2.68M 0.44% 65
2025
Q3 		$7.87M Sell
579,174
-70,826
-11% -$667K 0.82% 45
2025
Q2 		$4.17M Buy
+650,000
New +$3.16M 0.48% 66

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Parkman Healthcare Partners's AMLX Position: Q2 2026 in Review

Parkman Healthcare Partners reduced its Amylyx Pharmaceuticals (AMLX) stake by 36% in Q2 2026, selling an estimated $3.44M and leaving 398,782 shares worth $7.16M. The position accounts for 0.73% of the portfolio, ranked #48.

Parkman Healthcare Partners first reported a position in AMLX in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.64M in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Parkman Healthcare Partners held 398,782 shares of Amylyx Pharmaceuticals worth $7.16M as of Q2 2026.
  • Parkman Healthcare Partners sold 222,676 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $3.44M.
  • Amylyx Pharmaceuticals made up 0.73% of Parkman Healthcare Partners's portfolio in Q2 2026, its #48 holding.
  • Parkman Healthcare Partners first reported a position in Amylyx Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Parkman Healthcare Partners's Amylyx Pharmaceuticals position peaked at $8.64M in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.